

VU Research Portal

The end-of-life phase of high-grade glioma patients

Sizoo, E.M.

2013

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Sizoo, E. M. (2013). *The end-of-life phase of high-grade glioma patients: Towards a dignified death*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Reference List

1. Kohler BA, Ward E, McCarthy BJ et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. *J Natl Cancer Inst* 2011;103:714-36.
2. van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, Coebergh J. Incidence of primary central nervous system cancers in South and East Netherlands in 1989-1994. *Neuroepidemiology* 1998;17:247-57.
3. Houben MP, Aben KK, Teepen JL et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003. *Acta Oncol* 2006;45:272-9.
4. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. *Lancet* 2003;361:323-31.
5. Gravendeel LA, Kouwenhoven MC, Gevaert O et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. *Cancer Res* 2009;69:9065-72.
6. Gupta K, Salunke P. Molecular markers of glioma: an update on recent progress and perspectives. *J Cancer Res Clin Oncol* 2012;138:1971-81.
7. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. *J Neuropathol Exp Neurol* 2005;64:479-89.
8. van den Bent MJ, Brandes AA, Taphoorn MJ et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol* 2013;31:344-50.
9. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987-96.
10. Gorlia T, van den Bent MJ, Hegi ME et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *Lancet Oncol* 2008;9:29-38.
11. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. *Neurosurgery* 2008;62:753-64.
12. Brown PD, Maurer MJ, Rummans TA et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. *Neurosurgery* 2005;57:495-504.
13. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. *J Neurosurg* 1978;49:333-43.
14. Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. *Cancer* 1981;47:649-52.

15. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. *Radiother Oncol* 2002;64:259-73.
 16. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. *N Engl J Med* 2007;356:1527-35.
 17. Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. *Lancet Oncol* 2005;6:937-44.
 18. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. *Cochrane Database Syst Rev* 2008;CD007415.
 19. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. *J Clin Oncol* 2006;24:2715-22.
 20. Taphoorn MJ, van den Bent MJ, Mauer ME et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. *J Clin Oncol* 2007;25:5723-30.
 21. Faithfull S, Cook K, Lucas C. Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. *Palliat Med* 2005;19:545-50.
 22. World Health Organization (WHO). World Health Organization (WHO) definition on palliative care. <http://www.who.int/cancer/palliative/definition/en>. 1-1-2002. Geneva.
- Ref Type: Generic
23. Chochinov HM. Dying, dignity, and new horizons in palliative end-of-life care. *CA Cancer J Clin* 2006;56:84-103.
 24. Onwuteaka-Philipsen BD, Brinkman-Stoppelenburg A, Penning C, de Jong-Krul GJ, van Delden JJ, van der Heide A. Trends in end-of-life practices before and after the enactment of the euthanasia law in the Netherlands from 1990 to 2010: a repeated cross-sectional survey. *Lancet* 2012;380:908-15.
 25. Bausewein C, Hau P, Borasio GD, Voltz R. How do patients with primary brain tumours die? *Palliat Med* 2003;17:558-9.
 26. Davies E, Clarke C. Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. *J Neurol Neurosurg Psychiatry* 2005;76:555-61.
 27. Crocetti E, Trama A, Stiller C et al. Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer* 2012;48:1532-42.
 28. van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. *Neurol Clin* 2007;25:1089-x.
 29. Preusser M, de RS, Wohrer A et al. Current concepts and management of glioblastoma. *Ann Neurol* 2011;70:9-21.

30. Ricard D, Idbah A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. *Lancet* 2012;379:1984-96.
31. Sepulveda C, Marlin A, Yoshida T, Ullrich A. Palliative Care: the World Health Organization's global perspective. *J Pain Symptom Manage* 2002;24:91-6.
32. Foley KM, Carver AC. Palliative care in neurology. *Neurol Clin* 2001;19:789-99.
33. Becker G, Hatami I, Xander C et al. Palliative cancer care: an epidemiologic study. *J Clin Oncol* 2011;29:646-50.
34. Horowitz S, Passik SD, Malkin MG. 'In sickness and in health': A group intervention for spouses caring for patients with brain tumors. *J PSYCHOSOC ONCOL* 1996;14:43-56.
35. van der Heide A, Onwuteaka-Philipsen BD, Rurup ML et al. End-of-life practices in the Netherlands under the Euthanasia Act. *N Engl J Med* 2007;356:1957-65.
36. Taillandier L, Blonski M, Darlix A et al. Supportive care in neurooncology. *Rev Neurol (Paris)* 2011;167:762-72.
37. Taillibert S, Laigle-Donadey F, Sanson M. Palliative care in patients with primary brain tumors. *Curr Opin Oncol* 2004;16:587-92.
38. Chandana SR, Movva S, Arora M, Singh T. Primary brain tumors in adults. *Am Fam Physician* 2008;77:1423-30.
39. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. *Hematol Oncol Clin North Am* 2006;20:1337-61.
40. McNamara S. An overview of palliative care for patients with brain tumours: an interprofessional approach. *British Journal of Neuroscience Nursing* 2008;4:435-7.
41. Catt S, Chalmers A, Fallowfield L. Psychosocial and supportive-care needs in high-grade glioma. *Lancet Oncol* 2008;9:884-91.
42. Ford E, Catt S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. *Neuro Oncol* 2012;14:392-404.
43. Triebel KL, Martin RC, Nabors LB, Marson DC. Medical decision-making capacity in patients with malignant glioma. *Neurology* 2009;73:2086-92.
44. Pace A, Di LC, Capon A et al. Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: a cost effectiveness study. *J Palliat Med* 2012;15:225-7.
45. Cavers D, Hacking B, Erridge SC, Morris PG, Kendall M, Murray SA. Adjustment and support needs of glioma patients and their relatives: serial interviews. *Psychooncology* 2012.
46. Oberndorfer S, Lindeck-Pozza E, Lahrman H, Struhal W, Hitzenberger P, Grisold W. The end-of-life hospital setting in patients with glioblastoma. *J Palliat Med* 2008;11:26-30.
47. Sizoo EM, Braam L, Postma TJ et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. *Neuro Oncol* 2010;12:1162-6.

48. Pace A, Di LC, Guariglia L, Jandolo B, Carapella CM, Pompili A. End of life issues in brain tumor patients. *J Neurooncol* 2009;91:39-43.
49. Ostgathe C, Gaertner J, Kotterba M et al. Differential palliative care issues in patients with primary and secondary brain tumours. *Support Care Cancer* 2010;18:1157-63.
50. Arber A, Faithfull S, Plaskota M, Lucas C, de VK. A study of patients with a primary malignant brain tumour and their carers: symptoms and access to services. *Int J Palliat Nurs* 2010;16:24-30.
51. Gofton TE, Graber J, Carver A. Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. *J Neurooncol* 2012;108:527-34.
52. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. *Neuro Oncol* 2008;10:61-72.
53. Sherwood PR, Given BA, Doorenbos AZ, Given CW. Forgotten voices: lessons from bereaved caregivers of persons with a brain tumour. *Int J Palliat Nurs* 2004;10:67-75.
54. Salander P, Spetz A. How do patients and spouses deal with the serious facts of malignant glioma? *Palliat Med* 2002;16:305-13.
55. Addington-Hall J, Altmann D. Which terminally ill cancer patients in the United Kingdom receive care from community specialist palliative care nurses? *J Adv Nurs* 2000;32:799-806.
56. Sizoo EM, Pasman HR, Buttolo J et al. Decision-making in the end-of-life phase of high-grade glioma patients. *Eur J Cancer* 2012;48:226-32.
57. Pace A, Parisi C, Di LM et al. Home rehabilitation for brain tumor patients. *J Exp Clin Cancer Res* 2007;26:297-300.
58. Seeber AA, Hijdra A, Vermeulen M, Willems DL. Discussions about treatment restrictions in chronic neurologic diseases: a structured review. *Neurology* 2012;78:590-7.
59. Goodman C, Evans C, Wilcock J et al. End of life care for community dwelling older people with dementia: an integrated review. *Int J Geriatr Psychiatry* 2010;25:329-37.
60. Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: "prepare for the worst and hope for the best". *JAMA* 2007;298:207-16.
61. Gilbertson-White S, Aouizerat BE, Jahan T, Miaskowski C. A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. *Palliat Support Care* 2011;9:81-102.
62. Lorenz KA, Lynn J, Dy SM et al. Evidence for improving palliative care at the end of life: a systematic review. *Ann Intern Med* 2008;148:147-59.
63. Raijmakers NJ, van ZL, Costantini M et al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. *Ann Oncol* 2011;22:1478-86.
64. Johnston B, McGill M, Milligan S, McElroy D, Foster C, Kearney N. Self care and end of life care in advanced cancer: literature review. *Eur J Oncol Nurs* 2009;13:386-98.

65. Krouwer HG, Pallagi JL, Graves NM. Management of seizures in brain tumor patients at the end of life. *J Palliat Med* 2000;3:465-75.
66. Groot M.de, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. *Brain* 2012;135:1002-16.
67. Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. *Adv Drug Deliv Rev* 2012;64:911-8.
68. Janda M, Eakin EG, Bailey L, Walker D, Troy K. Supportive care needs of people with brain tumours and their carers. *Support Care Cancer* 2006;14:1094-103.
69. Singer PA, Robertson G, Roy DJ. Bioethics for clinicians: 6. Advance care planning. *CMAJ* 1996;155:1689-92.
70. Astrow AB, Sood JR, Nolan MT et al. Decision-making in patients with advanced cancer compared with amyotrophic lateral sclerosis. *J Med Ethics* 2008;34:664-8.
71. El-Jawahri A, Podgurski LM, Eichler AF et al. Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. *J Clin Oncol* 2010;28:305-10.
72. van der Heide A, de Vogel-Voogt E, Visser AP, van der Rijt CC, van der Maas PJ. Dying at home or in an institution: perspectives of Dutch physicians and bereaved relatives. *Support Care Cancer* 2007;15:1413-21.
73. van den Bent MJ, Reni M, Gatta G, Vecht C. Oligodendroglioma. *Crit Rev Oncol Hematol* 2008;66:262-72.
74. Correa DD. Cognitive functions in brain tumor patients. *Hematol Oncol Clin North Am* 2006;20:1363-76.
75. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. *J Neurooncol* 2002;57:41-9.
76. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. *Neuro Oncol* 2000;2:221-8.
77. Janda M, Steginga S, Langbecker D, Dunn J, Walker D, Eakin E. Quality of life among patients with a brain tumor and their carers. *J Psychosom Res* 2007;63:617-23.
78. Leidy NK, Elixhauser A, Vickrey B, Means E, Willian MK. Seizure frequency and the health-related quality of life of adults with epilepsy. *Neurology* 1999;53:162-6.
79. Heimans JJ, Taphoorn MJ. Impact of brain tumour treatment on quality of life. *J Neurol* 2002;249:955-60.
80. Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. *Eur J Cancer* 2002;38:1824-31.
81. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. *J Neurol* 1997;244 Suppl 4:S2-10.:S2-10.

82. Cohen J, Bilsen J, Addington-Hall J et al. Population-based study of dying in hospital in six European countries. *Palliat Med* 2008;22:702-10.
83. van der Heide A, de Vogel-Voogt E, Visser AP, van der Rijt CC, van der Maas PJ. Dying at home or in an institution: perspectives of Dutch physicians and bereaved relatives. *Support Care Cancer* 2007;15:1413-21.
84. Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. *Am Fam Physician* 2001;64:1019-26.
85. Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting. *Am Fam Physician* 2001;64:807-14.
86. Kapo J, Morrison LJ, Liao S. Palliative care for the older adult. *J Palliat Med* 2007;10:185-209.
87. Jimenez-Gordo AM, Feliu J, Martinez B et al. Descriptive analysis of clinical factors affecting terminally ill cancer patients. *Support Care Cancer* 2009;17:261-9.
88. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. *Lancet Neurol* 2007;6:421-30.
89. Riva M, Salmaggi A, Marchioni E et al. Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. *Neurol Sci* 2006;27:345-51.
90. Klein M, Engelberts NH, van der Ploeg HM et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. *Ann Neurol* 2003;54:514-20.
91. Earle CC, Ayanian JZ. Looking back from death: the value of retrospective studies of end-of-life care. *J Clin Oncol* 2006;24:838-40.
92. Pace A, Villani V, Di LC et al. Epilepsy in the end-of-life phase in patients with high-grade gliomas. *J Neurooncol* 2013;111:83-6.
93. Bottomley A, Flechtner H, Efficace F et al. Health related quality of life outcomes in cancer clinical trials. *Eur J Cancer* 2005;41:1697-709.
94. Grant R, Slattery J, Gregor A, Whittle IR. Recording neurological impairment in clinical trials of glioma. *J Neurooncol* 1994;19:37-49.
95. MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. *Md State Med J* 1965;14:61-5.:61-5.
96. Karnofsky DA BJH. "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." . Columbia Univ Press, 1949.
97. RANKIN J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. *Scott Med J* 1957;2:200-15.
98. Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. *J Chronic Dis* 1981;34:585-97.

99. Aaronson NK. Quality of life: what is it? How should it be measured? *Oncology (Williston Park)* 1988;2:69-76, 64.
100. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365-76.
101. Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. *Qual Life Res* 1996;5:139-50.
102. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. *Cancer* 1995;75:1151-61.
103. Armstrong TS, Mendoza T, Gning I et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). *J Neurooncol* 2006;80:27-35.
104. Armstrong TS, Gning I, Mendoza TR et al. Clinical utility of the MDASI-BT in patients with brain metastases. *J Pain Symptom Manage* 2009;37:331-40.
105. Sneeuw KC, Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. *J Clin Epidemiol* 2002;55:1130-43.
106. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. *J Neurooncol* 1997;34:263-78.
107. Brown PD, Decker PA, Rummans TA et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. *Am J Clin Oncol* 2008;31:163-8.
108. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. *J Neurooncol* 2003;63:179-86.
109. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. *Lancet Neurol* 2004;3:159-68.
110. Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. *J Neurol Neurosurg Psychiatry* 2005;76:562-8.
111. Brown PD, Ballman KV, Rummans TA et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. *J Neurooncol* 2006;76:283-91.
112. Klein M, Taphoorn MJ, Heimans JJ et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. *J Clin Oncol* 2001;19:4037-47.
113. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumour. *J Neurol Neurosurg Psychiatry* 1999;67:358-63.

114. Salo J, Niemela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients' perceived quality of life. *J Neurol Neurosurg Psychiatry* 2002;72:373-7.
115. Gupta D, Lis CG, Grutsch JF. The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. *J Pain Symptom Manage* 2007;34:40-7.
116. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. *J Clin Oncol* 2000;18:1481-91.
117. Bosma I, Reijneveld JC, Douw L et al. Health-related quality of life of long-term high-grade glioma survivors. *Neuro Oncol* 2009;11:51-8.
118. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. *Crit Rev Oncol Hematol* 2006;60:181-93.
119. Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. *J Neurooncol* 2007;81:287-94.
120. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. *Eur J Cancer* 2000;36:1788-95.
121. Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. *Lancet* 2002;360:1361-8.
122. Kaal EC, Vecht CJ. The management of brain edema in brain tumors. *Curr Opin Oncol* 2004;16:593-600.
123. Mauer M, Stupp R, Taphoorn MJ et al. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. *Br J Cancer* 2007;97:302-7.
124. Sehlen S, Lenk M, Hollenhorst H et al. Quality of life (QoL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. *Onkologie* 2003;26:38-43.
125. Mauer ME, Taphoorn MJ, Bottomley A et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. *J Clin Oncol* 2007;25:5731-7.
126. Velikova G, Awad N, Coles-Gale R, Wright EP, Brown JM, Selby PJ. The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. *Psychooncology* 2008;17:690-8.
127. World Health Organization (WHO) definition of Palliative Care. World Health Organization (WHO) definition of Palliative Care. Geneva: WHO 2002. <http://www.who.int/cancer/palliative/definition/en>. 2002.

Ref Type: Online Source

128. Albers G, Echteld MA, de Vet HC, Onwuteaka-Philipsen BD, van der Linden MH, Deliens L. Content and spiritual items of quality-of-life instruments appropriate for use in palliative care: a review. *J Pain Symptom Manage* 2010;40:290-300.
129. Steinhauser KE, Clipp EC, Tulsky JA. Evolution in measuring the quality of dying. *J Palliat Med* 2002;5:407-14.
130. Stewart AL, Teno J, Patrick DL, Lynn J. The concept of quality of life of dying persons in the context of health care. *J Pain Symptom Manage* 1999;17:93-108.
131. Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. *Oncologist* 2010;15:618-26.
132. Byock IR, Merriman MP. Measuring quality of life for patients with terminal illness: the Missoula-VITAS quality of life index. *Palliat Med* 1998;12:231-44.
133. Steinhauser KE, Bosworth HB, Clipp EC et al. Initial assessment of a new instrument to measure quality of life at the end of life. *J Palliat Med* 2002;5:829-41.
134. Cohen SR, Mount BM, Bruera E, Provost M, Rowe J, Tong K. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. *Palliat Med* 1997;11:3-20.
135. Sterkenburg CA, King B, Woodward CA. A reliability and validity study of the McMaster Quality of Life Scale (MQLS) for a palliative population. *J Palliat Care* 1996;12:18-25.
136. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press. 1993.
137. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473-83.
138. van Wijmen MP, Rurup ML, Pasma HR, Kaspers PJ, Onwuteaka-Philipsen BD. Design of the Advance Directives Cohort: a study of end-of-life decision-making focusing on Advance Directives. *BMC Public Health* 2010;10:166. doi: 10.1186/1471-2458-10-166.:166-10.
139. Mookkink LB, Terwee CB, Patrick DL et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. *J Clin Epidemiol* 2010;63:737-45.
140. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organization for Research and Treatment of Cancer. 2001.
141. Fayers P, Machin D. Quality of Life. Assessment, Analysis and Interpretation. Chichester, John Wiley and Sons, 2000.
142. Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. *J Clin Epidemiol* 1998;51:617-31.
143. Sneeuw KC, Aaronson NK, Osoba D et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. *Med Care* 1997;35:490-506.

144. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? *Qual Life Res* 1997;6:225-36.
145. Giesinger JM, Golser M, Erharter A et al. Do neurooncological patients and their significant others agree on quality of life ratings? *Health Qual Life Outcomes* 2009;7:87.
146. Milne DJ, Mulder LL, Beelen HC, Schofield P, Kempen GI, Aranda S. Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare? *Eur J Cancer Care (Engl)* 2006;15:125-32.
147. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. *J Clin Epidemiol* 1992;45:743-60.
148. Sizoo EM, Taphoorn MJ, Uitdehaag B et al. The end-of-life phase of high-grade glioma patients: dying with dignity? *Oncologist* 2013;18:198-203.
149. van der Maas PJ, van der Wal G, Haverkate I et al. Euthanasia, physician-assisted suicide, and other medical practices involving the end of life in the Netherlands, 1990-1995. *N Engl J Med* 1996;335:1699-705.
150. van der Heide A, Deliens L, Faisst K et al. End-of-life decision-making in six European countries: descriptive study. *Lancet* 2003;362:345-50.
151. Kerrigan S, Ormerod I. Advance planning in end-of-life care: legal and ethical considerations for neurologists. *Pract Neurol* 2010;10:140-4.
152. Onwuteaka-Philipsen BD, van der Heide A, Koper D et al. Euthanasia and other end-of-life decisions in the Netherlands in 1990, 1995, and 2001. *Lancet* 2003;362:395-9.
153. Taphoorn MJ, Claassens L, Aaronson NK et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *Eur J Cancer* 2010;46:1033-40.
154. Abarshi E, Echteld M, Donker G, Van den Block L, Onwuteaka-Philipsen B, Deliens L. Discussing end-of-life issues in the last months of life: a nationwide study among general practitioners. *J Palliat Med* 2011;14:323-30.
155. Back AL, Anderson WG, Bunch L et al. Communication about cancer near the end of life. *Cancer* 2008;113:1897-910.
156. Pace A, Metro G, Fabi A. Supportive care in neurooncology. *Curr Opin Oncol* 2010;22:621-6.
157. Engstrom J, Bruno E, Holm B, Hellzen O. Palliative sedation at end of life - a systematic literature review. *Eur J Oncol Nurs* 2007;11:26-35.
158. Van den Block L, Bilsen J, Deschepper R, Van der Kelen G, Bernheim JL, Deliens L. End-of-life decisions among cancer patients compared with noncancer patients in Flanders, Belgium. *J Clin Oncol* 2006;24:2842-8.
159. Maessen M, Veldink JH, Onwuteaka-Philipsen BD et al. Trends and determinants of end-of-life practices in ALS in the Netherlands. *Neurology* 2009;73:954-61.

160. Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, Van den Berg LH. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. *N Engl J Med* 2002;346:1638-44.
161. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. *Lancet Oncol* 2003;4:312-8.
162. Rietjens JA, van der Heide A, Onwuteaka-Philipsen BD, van der Maas PJ, van der Wal G. Preferences of the Dutch general public for a good death and associations with attitudes towards end-of-life decision-making. *Palliat Med* 2006;20:685-92.
163. Pullman D. Human dignity and the ethics and aesthetics of pain and suffering. *Theor Med Bioeth* 2002;23:75-94.
164. Chochinov HM, Hack T, McClement S, Kristjanson L, Harlos M. Dignity in the terminally ill: a developing empirical model. *Soc Sci Med* 2002;54:433-43.
165. Albers G, Pasman HR, Rurup ML, de Vet HC, Onwuteaka-Philipsen BD. Analysis of the construct of dignity and content validity of the patient dignity inventory. *Health Qual Life Outcomes* 2011;9:45. doi: 10.1186/1477-7525-9-45.
166. Vlug MG, de Vet HC, Pasman HR, Rurup ML, Onwuteaka-Philipsen BD. The development of an instrument to measure factors that influence self-perceived dignity. *J Palliat Med* 2011;14:578-86.
167. Periyakoil VS, Noda AM, Kraemer HC. Assessment of factors influencing preservation of dignity at life's end: creation and the cross-cultural validation of the preservation of dignity card-sort tool. *J Palliat Med* 2010;13:495-500.
168. Fayers PM, Aaronson NK, Bjordal K. The EORTC QLQ-C30 Scoring Manual. Third Edition. European Organisation for Research and Treatment of Cancer Quality of Life Group, editor. 2001. Brussels, Belgium.

Ref Type: Generic

169. Chochinov HM, Hack T, Hassard T, Kristjanson LJ, McClement S, Harlos M. Dignity in the terminally ill: a cross-sectional, cohort study. *Lancet* 2002;360:2026-30.
170. Periyakoil VS, Kraemer HC, Noda A. Creation and the empirical validation of the dignity card-sort tool to assess factors influencing erosion of dignity at life's end. *J Palliat Med* 2009;12:1125-30.
171. Mack JW, Weeks JC, Wright AA, Block SD, Prigerson HG. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. *J Clin Oncol* 2010;28:1203-8.
172. Wright AA, Zhang B, Ray A et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. *JAMA* 2008;300:1665-73.
173. Hall S, Longhurst S, Higginson I. Living and dying with dignity: a qualitative study of the views of older people in nursing homes. *Age Ageing* 2009;38:411-6.

174. Arber A, Hutson N, de VK, Guerrero D. Finding the right kind of support: A study of carers of those with a primary malignant brain tumour. *EUR J ONCOL NURS* 2012.
175. Slort W, Schweitzer BP, Blankenstein AH et al. Perceived barriers and facilitators for general practitioner-patient communication in palliative care: a systematic review. *Palliat Med* 2011;25:613-29.
176. Slort W, Blankenstein AH, Deliens L, van der Horst HE. Facilitators and barriers for GP-patient communication in palliative care: a qualitative study among GPs, patients, and end-of-life consultants. *Br J Gen Pract* 2011;61:167-72.
177. van der Steen JT, Ribbe MW, Deliens L, Gutschow G, Onwuteaka-Philipsen BD. Retrospective and Prospective Data Collection Compared in the Dutch End of Life in Dementia (DEOLD) Study. *Alzheimer Dis Assoc Disord* 2013.
178. Fayers P MD. *Quality of Life. Assessment, Analysis and Interpretation*. Chichester: Jon Wiley and Sons, 2000.
179. Albers G, Harding R, Pasman HR et al. What is the methodological rigour of palliative care research in long-term care facilities in Europe? A systematic review. *Palliat Med* 2012;26:722-33.
180. Kutner JS, Bryant LL, Beaty BL, Fairclough DL. Symptom distress and quality-of-life assessment at the end of life: the role of proxy response. *J Pain Symptom Manage* 2006;32:300-10.
181. Higginson I, Priest P, McCarthy M. Are bereaved family members a valid proxy for a patient's assessment of dying? *Soc Sci Med* 1994;38:553-7.
182. Rooney AG, McNamara S, Mackinnon M et al. Screening for major depressive disorder in adults with glioma using the PHQ-9: a comparison of patient versus proxy reports. *J Neurooncol* 2013;113:49-55.
183. McPherson CJ, Addington-Hall JM. How do proxies' perceptions of patients' pain, anxiety, and depression change during the bereavement period? *J Palliat Care* 2004;20:12-9.
184. Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. *Intern Med J* 2005;35:512-7.
185. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. *J Pain Symptom Manage* 2001;21:282-9.
186. Lynn J, Adamson D. *Living Well at the End of Life: Adapting Health Care to Serious Chronic Illness in Old Age*. Santa Monica, CA: RAND Corporation, 2003
187. Madsen K, Poulsen HS. Needs for everyday life support for brain tumour patients' relatives: systematic literature review. *Eur J Cancer Care (Engl)* 2011;20:33-43.
188. Spetz A, Henriksson R, Bergenheim AT, Salander P. A specialist nurse-function in neurooncology: a qualitative study of possibilities, limitations, and pitfalls. *Palliat Support Care* 2005;3:121-30.

189. Temel JS, Greer JA, Admane S et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. *J Clin Oncol* 2011;29:2319-26.
190. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733-42.
191. Flechl B, Ackerl M, Sax C et al. The caregivers' perspective on the end-of-life phase of glioblastoma patients. *J Neurooncol* 2013;112:403-11.
192. Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. *Curr Opin Neurol* 2010;23:597-602.
193. Javier NS, Montagnini ML. Rehabilitation of the hospice and palliative care patient. *J Palliat Med* 2011;14:638-48.
194. van den Berg JP, Kalmijn S, Lindeman E, Wokke JH, Van den Berg LH. Rehabilitation care for patients with ALS in The Netherlands. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2003;4:186-90.
195. van den Berg JP, de Groot IJ, Joha BC, van Haelst JM, van GP, Kalmijn S. Development and implementation of the Dutch protocol for rehabilitative management in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2004;5:226-9.
196. van den Berg JP, Kalmijn S, Lindeman E et al. Multidisciplinary ALS care improves quality of life in patients with ALS. *Neurology* 2005;65:1264-7.
197. Mukand JA, Blackinton DD, Crincoli MG, Lee JJ, Santos BB. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. *Am J Phys Med Rehabil* 2001;80:346-50.
198. Greenberg E, Treger I, Ring H. Rehabilitation outcomes in patients with brain tumors and acute stroke: comparative study of inpatient rehabilitation. *Am J Phys Med Rehabil* 2006;85:568-73.
199. Gehring K, Patwardhan SY, Collins R et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. *J Neurooncol* 2012;107:165-74.
200. Boele FW, Douw L, Groot Md et al. The effect of modafinil on fatigue, cognitive functioning and mood in primary brain tumor patients: a multi-center RCT. *Neuro Oncol*. In press.
201. Gehring K, Sitskoorn MM, Gundy CM et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. *J Clin Oncol* 2009;27:3712-22.
202. Bruera E, Bush SH, Willey J et al. Impact of Delirium and recall on the level or distress in patients with advanced cancer and their family caregivers. *Cancer* 2009;115:2004-12.
203. Cobb JL, Glantz MJ, Nicholas PK et al. Delirium in patients with cancer at the end of life. *Cancer Pract* 2000;8:172-7.
204. Namba M, Morita T, Imura C, Kiyohara E, Ishikawa S, Hirai K. Terminal delirium: families' experience. *Palliat Med* 2007;21:587-94.

205. Morita T, Akechi T, Ikenaga M et al. Terminal delirium: recommendations from bereaved families' experiences. *J Pain Symptom Manage* 2007;34:579-89.
206. Lawlor PG, Fainsinger RL, Bruera ED. Delirium at the end of life: critical issues in clinical practice and research. *JAMA* 2000;284:2427-9.
207. Lawlor PG, Bruera ED. Delirium in patients with advanced cancer. *Hematol Oncol Clin North Am* 2002;16:701-14.
208. Breitbart W, Alici Y. Agitation and delirium at the end of life: "We couldn't manage him". *JAMA* 2008;300:2898-910, E1.
209. Voltz R, Borasio GD. Palliative therapy in the terminal stage of neurological disease. *J Neurol* 1997;244 Suppl 4:S2-10.
210. Daud ML. Drug management of terminal symptoms in advanced cancer patients. *Curr Opin Support Palliat Care* 2007;1:202-6.
211. Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. *Am Fam Physician* 2001;64:1019-26.
212. Casarett DJ, Inouye SK. Diagnosis and management of delirium near the end of life. *Ann Intern Med* 2001;135:32-40.
213. Keeley PW. Delirium at the end of life. *Clin Evid (Online)* 2007;2007.
214. Rooney AG, McNamara S, Mackinnon M et al. Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma. *J Clin Oncol* 2011;29:4307-12.
215. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic review of observational studies. *J Natl Cancer Inst* 2011;103:61-76.
216. Sizoo EM, Koekkoek JAF, Postma TJ et al. Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase. *BMJ Supp Pal Care*. In press.
217. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *BMJ* 2010;340:c1345. doi: 10.1136/bmj.c1345.:c1345.
218. Maltoni M, Scarpi E, Rosati M et al. Palliative sedation in end-of-life care and survival: a systematic review. *J Clin Oncol* 2012;%20;30:1378-83.
219. van Gennip IE, Roeline H, Pasma W et al. Death with dignity from the perspective of the surviving family: A survey study among family caregivers of deceased older adults. *Palliat Med* 2013.
220. Abarshi E, Echteld M, Van den Block L, Donker G, Deliëns L, Onwuteaka-Philipsen B. Transitions between care settings at the end of life in the Netherlands: results from a nationwide study. *Palliat Med* 2010;24:166-74.

221. Boele FW, Hoeben W, Hilverda K et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma patients: a randomized controlled trial. *J Neurooncol* 2013;111:303-11.